Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 12, 881 - 882 (2006)
doi:10.1038/nm0806-881
Targeted cancer therapeutics: the heartbreak of success
Douglas L Mann1
- The author is in the Winters Center for Heart Failure Research, Section of Cardiology, Department of Medicine, Baylor College of Medicine and the Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA. e-mail: dmann@bcm.tmc.edu
Abstract
Tyrosine kinase inhibitors, widely hailed for their success as treatments for cancer, are also plagued by the issue of cardiotoxic side effects. The mechanism behind the heart damage now comes to light for one such inhibitor, imatinib mesylate, also known as Gleevec (pages 908–916).
One of the exciting developments in cancer research has been the clinical validation of drugs that target and inhibit oncogenic tyrosine kinases. Treatment of appropriately selected patients with these agents not only alters the natural history of the disease, but also improves survival.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Cardiotoxicity of the cancer therapeutic agent imatinib mesylateNature Medicine Article (01 Aug 2006)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Nature Medicine Correspondence (01 Jan 2007)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Nature Medicine Correspondence (01 Jan 2007)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Nature Medicine Correspondence (01 Jan 2007)
See all 7 matches for Research